A COMPARISON OF METHODOLOGIES FOR ESTIMATING SURVIVAL IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE-KINASE INHIBITORS (TKIS) FOR CHRONIC MYELOID LEUKAEMIA (CML)

被引：0
|
作者：
Pennington, B. [1 ]
Batty, A. J. [1 ]
Clifton-Brown, E. [2 ]
机构：
[1] BresMed, Sheffield, S Yorkshire, England
[2] Pfizer Ltd, Tadworth, England
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.023
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A326 / A327
页数：2
相关论文
共 50 条
  • [1] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 17 - 26
  • [2] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Abruzzese, Elisabetta
    Breccia, Massimo
    Latagliata, Roberto
    BIODRUGS, 2014, 28 (01) : 17 - 26
  • [3] Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 325 - 325
  • [4] No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
    Iglesias, Lilian
    Mukherjee, Sudipto
    Nazha, Aziz
    Advani, Anjali S.
    Gerds, Aaron T.
    Carraway, Hetty E.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Majhail, Navneet S.
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [5] Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Jung, Y. S.
    Kim, M.
    Lee, J. H.
    Kim, D. W.
    Park, H. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (02) : 456 - 458
  • [6] Second-generation tyrosine-kinase inhibitors and combinations: perspectives
    Coiteux, V.
    ONCOLOGIE, 2012, 14 (10-11) : 601 - 605
  • [7] Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Sam, Princy Yohannan
    Ahaneku, Hycienth
    Nogueras-Gonzalez, Graciela M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Kadia, Tapan
    Burger, Jan
    Pierce, Sherry
    DiNardo, Courtney D.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [8] Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs)
    Wetzler, Meir
    Kantarjian, Hagop
    Nicolini, Franck E.
    Lipton, Jeffrey Howard
    Akard, Luke Paul
    Baccarani, Michele
    Craig, Adam
    Brown, Peter D.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Fava, Carmen
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Wierda, William
    Thomas, Deborah
    Shan, Jianquin
    Cortes, Jorge
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) : 303 - 312
  • [10] Treatment by second-generation tyrosine-kinase inhibitors in patients with imatinib failure
    Etienne, G.
    ONCOLOGIE, 2012, 14 (10-11) : 589 - 595
12345